A Twelve Month Long Term Safety Study to Evaluate the Safety of Albuterol in a Dry Powder Inhaler With Both Repeated and as Needed Dosing

NCT01218009 | Terminated Phase 3 Results

• 1 other identifier: ABS-AS-306
• Study Type: interventional
• Target: 331
• Locations: 1 country
• Sites: 30

Brief Summary

This is a one-year study to look at the safety of a dry powder inhaler with albuterol. After a one-week run in, for the first 3 months subjects will use an inhaler with either albuterol or a dummy drug at regular times four times a day. Then for the last nine months of the study, all subjects will be given the albuterol dry powder inhaler and will use it only when needed to help with breathing problems. Subjects will need to keep a daily diary (both paper and electronic) throughout the study recording any inhaler use and health problems. There will be visits to the study doctor about once a month for a year. This study is intended to show that the albuterol dry powder inhaler works well and is safe for use over a long period of time.

Conditions

Asthma

Keywords

asthma; dry powder inhaler; short-acting beta2-agonist; SABA; bronchoconstriction; bronchodilation; bronchodilator; metered dose inhaler

Outcome Measures

Primary Outcomes (5)

• Participants With Treatment-Emergent Adverse Events

  Adverse events (AEs) summarized in this table are those that began or worsened after treatment with study drug (treatment-emergent AEs). An adverse event was defined in the protocol as any untoward medical occurrence that develops or worsens in severity during the conduct of a clinical study and does not necessarily have a causal relationship to the study drug. Severity was rated by the investigator on a scale of mild, moderate and severe, with severe= an AE which prevents normal daily activities. Relation of AE to treatment was determined by the investigator. Serious AEs include death, a life-threatening adverse event, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, a congenital anomaly or birth defect, OR an important medical event that jeopardized the patient and required medical intervention to prevent the previously listed serious outcomes.

  Day 1 to Day 49 (study termination)

• Changes From Screening in the Results of the Physical Examination That Are Clinically Significant in the Opinion of the Investigator

  A complete physical examination was planned at study screening, week 12 and week 52 or early termination/discontinuation of the participant. At weeks 12 and 52,the qualified healthcare professional was to evaluate whether each physical finding is a new finding, worsening, improvement or resolution of an existing condition compared with the baseline physical exam. Where possible, the same qualified healthcare professional that performed the physical examination at study screening should perform all the scheduled physical examinations.

  Days -15 to -8 (Screening), Week 12, Week 52

• Changes From Screening in the Results of the Laboratory Evaluations That Are Clinically Significant in the Opinion of the Investigator

  Blood samples were to collected for laboratory evaluations at the screening visit and at weeks 12 and 52 or early termination/discontinuation of the participant. The blood samples were to be drawn after an overnight fast of at least 6 hours and analyzed by a central laboratory.

  Days -15 to -8 (Screening), Week 12, Week 52

• Changes From Screening in the Results of the Electrocardiograms (ECGs) That Are Clinically Significant in the Opinion of the Investigator

  A standard 12-lead ECG was to be performed at screening and at week 12 and week 52 (TV15) or early termination/discontinuation of the participant. The ECG recording methods were to be centralized and standardized across all study subjects.

  Days -15 to -8 (Screening), Week 12, Week 52

• Changes From Screening in the Vital Signs That Are Clinically Significant in the Opinion of the Investigator

  Vital sign measurements (heart rate and blood pressure) were to be evaluated as part of the safety profile assessment. The participant was to be seated at least 2 minutes before vital signs were performed. Either an electronic or manual sphygmomanometer could be used.

  Days -15 to -8 (Screening), Week 12, Week 52

Study Arms (2)

Albuterol Spiromax

EXPERIMENTAL

Albuterol multi-dose dry powder inhaler (Spiromax) at a dose of 720 micrograms per day administered as 2 inhalations of 90 mcg /inhalation four times a day for the 12 week double-blind period. Participants then continue into the 40 week open-label period in which they take albuterol multi-dose dry powder inhaler (Spiromax) inhalations of 90 mcg /inhalation as required (PRN).

Drug: Albuterol Spiromax

Placebo Spiromax

PLACEBO COMPARATOR

Placebo delivered using a multi-dose dry powder inhaler (Spiromax) as 2 inhalations four times a day for the 12 week double-blind period. Participants then continue into the 40 week open-label period in which they administer albuterol multi-dose dry powder inhaler (Spiromax) inhalations of 90 mcg /inhalation as required (PRN).

Drug: Placebo Spiromax; Drug: Albuterol Spiromax

Interventions

Placebo Spiromax DRUG

Placebo as a dry-powder inhaled orally using the Spiromax inhaler. During the 12-week double-blind period, participants take two (2) inhalations four times a day (QID) at approximately 7:00 AM, 12:00 PM, 5:00 PM, and bedtime.

Placebo Spiromax

Albuterol Spiromax DRUG

Albuterol as a dry-powder inhaled orally using the Spiromax inhaler. Each inhalation delivers 90 micrograms (mcg). During the 12-week double-blind period, participants take two (2) inhalations four times a day (QID) at approximately 7:00 AM, 12:00 PM, 5:00 PM, and bedtime for a total dose of 720 micrograms per day for those paricipants randomized to the Albuterol treatment arm. The double-blind period is followed by a 40-week open-label period in which all study participants will take Albuterol Spiromax 90 micrograms (mcg)/inhalation as needed (PRN).

Also known as: ProAir® RespiClick, Albuterol multi-dose dry powder inhaler (MDPI)

Albuterol Spiromax; Placebo Spiromax

Eligibility Criteria

• Age: 12 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

• Documented history of persistent asthma with rescue use of albuterol on average of at least once/ week over the 4-weeks prior to screening.
• Female subjects who are of childbearing potential (as judged by the investigator) must be currently using and willing to continue to use a medically reliable method of contraception for the entire study duration
• General good health
• Capable of understanding the requirements, risks, and benefits of study participation
• Non-smoker for at least one year prior to the screening visit and a maximum pack-year smoking history of 10 years
• Other criteria apply

You may not qualify if:

• Pregnancy, nursing, or plans to become pregnant or donate gametes (ova or sperm) for in vitro fertilization during the study period or for 30 days following the subject's last study related visit
• Participation in any investigational drug trial within 30 days preceding the screening visit
• A known hypersensitivity to albuterol or any of the excipients in the formulations.
• History of severe milk protein allergy
• History of a respiratory infection or disorder (including, but not limited to bronchitis, pneumonia, acute or chronic sinusitis, otitis media, influenza, etc) which is not resolved within 1 week prior to the Screening Visit.
• Use of any protocol prohibited concomitant medications for asthma or any protocol prohibited concomitant non-asthma medications
• Inability to tolerate or unwillingness to comply with the protocol requirements.
• History of life-threatening asthma
• Any asthma exacerbation within 3 months of the Screening Visit requiring oral or systemic corticosteroids
• History of life-threatening asthma
• Other criteria apply

Sponsors & Collaborators

• Teva Branded Pharmaceutical Products R&D, Inc.: lead

Study Sites (30)

Teva Clinical Study Site

Scottsdale, Arizona, United States

Location

Teva Clinical Study Site

Los Angeles, California, United States

Location

Teva Clinical Study Site

San Diego, California, United States

Location

Teva Clinical Study Site

Centennial, Colorado, United States

Location

Teva Clinical Study Site

Denver, Colorado, United States

Location

Teva Clinical Study Site

Miami, Florida, United States

Location

Teva Clinical Study Site

Gainesville, Georgia, United States

Location

Teva Clinical Study Site

Louisville, Kentucky, United States

Location

Teva Clinical Study Site

Wheaton, Maryland, United States

Location

Teva Clinical Study Site

Minneapolis, Minnesota, United States

Location

Teva Clinical Study Site

Plymouth, Minnesota, United States

Location

Teva Clinical Study Site

St Louis, Missouri, United States

Location

Teva Clinical Study Site

Bellevue, Nebraska, United States

Location

Teva Clinical Study Site

Boys Town, Nebraska, United States

Location

Teva Clinical Study Site

Skillman, New Jersey, United States

Location

Teva Clinical Study Site

Rochester, New York, United States

Location

Teva Clinical Study Site

Rockville Centre, New York, United States

Location

Teva Clinical Study Site

High Point, North Carolina, United States

Location

Teva Clinical Study Site

Raleigh, North Carolina, United States

Location

Teva Clinical Study Site

Canton, Ohio, United States

Location

Teva Clinical Study Site

Cincinnati, Ohio, United States

Location

Teva Clinical Study Site

Sylvania, Ohio, United States

Location

Teva Clinical Study Site

Eugene, Oregon, United States

Location

Teva Clinical Study Site

Portland, Oregon, United States

Location

Teva Clinical Study Site

El Paso, Texas, United States

Location

Teva Clinical Study Site

New Braunfels, Texas, United States

Location

Teva Clinical Study Site

San Antonio, Texas, United States

Location

Teva Clinical Study Site

Burke, Virginia, United States

Location

Teva Clinical Study Site

Seattle, Washington, United States

Location

Teva Clinical Study Site

Greenfield, Wisconsin, United States

Location

MeSH Terms

Conditions

Asthma

Condition Hierarchy (Ancestors)

Bronchial Diseases; Respiratory Tract Diseases; Lung Diseases, Obstructive; Lung Diseases; Respiratory Hypersensitivity; Hypersensitivity, Immediate; Hypersensitivity; Immune System Diseases

Results Point of Contact

• Title: Director, Clinical Research
• Organization: Teva Branded Pharmaceutical Products, R&D Inc.

ustevatrials@tevapharm.com

1-215-591-3000

Study Officials

• Clinical Project Leader

  Teva Respiratory R&D

  STUDY DIRECTOR

Publication Agreements

• PI is Sponsor Employee: No
• Restriction Type: OTHER
• Restrictive Agreement: Yes

Study Design

• Study Type: interventional
• Phase: phase 3
• Allocation: RANDOMIZED
• Masking: QUADRUPLE
• Who Masked: PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: October 7, 2010
• First Posted: October 8, 2010
• Study Start: October 1, 2010
• Primary Completion: December 1, 2010
• Study Completion: December 1, 2010
• Last Updated: May 20, 2015
• Results First Posted: May 20, 2015

Record last verified: 2015-05

Locations

US (30)